LitCovid-sentences  

PMC:7170415 / 8440-10260 JSONTXT 6 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function

Id Subject Object Predicate Lexical cue
T64 0-194 Sentence denotes Despite the remarkable speed with which accurate diagnostic tests have been developed and made available for SARS–CoV-2 (25), current tools only partially meet several clinically relevant needs.
T65 195-309 Sentence denotes Figure 1 illustrates different indications for diagnostic testing among persons with proven or suspected COVID-19.
T66 310-421 Sentence denotes For each of these, the most important consideration is the clinical decision a test result will help to inform.
T67 422-889 Sentence denotes Test designs must account for several parameters, such as whether the test detects infection directly (such as the virus itself) or indirectly (such as host antibodies), test turnaround time, the ability to perform many tests at the same time (that is, throughput), the need to have a minimum number of specimens before testing (that is, batching), and the ability to perform the test in low-infrastructure settings (such as on cruise ships or in remote communities).
T68 890-960 Sentence denotes The potential for use at the point of care depends on test complexity.
T69 961-969 Sentence denotes The U.S.
T70 970-1054 Sentence denotes Food and Drug Administration (FDA) categorizes diagnostic tests by their complexity:
T71 1055-1190 Sentence denotes Waived tests are available for use at the point of care, whereas moderate- and high-complexity tests must be performed in a laboratory.
T72 1191-1267 Sentence denotes The intended use also determines which specimen types are ideal or feasible.
T73 1268-1387 Sentence denotes Finally, it is important to recognize that the acceptable diagnostic accuracy of a test may vary according to use case.
T74 1388-1657 Sentence denotes For example, sensitivity and specificity requirements of an assay used to confirm results of a screening test need not be as stringent as those of a method used for standalone diagnosis, because the pool of persons being tested is already enriched with true infections.
T75 1658-1820 Sentence denotes The Foundation for Innovative New Diagnostics has published a detailed assessment of priority use cases to be considered by test developers and policymakers (26).